ABSTRACT
Although the benefits of statins in reducing major cardiovascular adverse events following acute myocardial infarction have been well established, 1 utilization and adherence to statins is often sub-optimal and declines over time. [2] [3] [4] [5] [6] Poor adherence to statins has been associated with increased risks of repeat hospitalizations, cardiovascular (CV) events and increased medical costs. 3, [7] [8] [9] [10] [11] [12] [13] Adherence is generally higher in individuals with high mortality risks compared to those at lower mortality risks. [16] [17] [18] Reuter et al. showed that 88% of survivors of ST-segment elevation myocardial infarction (STEMI) were still taking statins at 36-month. 18 However, very limited data is available regarding longer term statin adherence.
Factors associated with poor adherence to statins are numerous and include age, adverse events, copayment, socio-economic factors, new statin use, primary prevention, co-morbidities, and concomitant medications. [16] [17] [19] [20] [21] Direct costs incurred by patients are often cited as responsible for non-to poor adherence to statins. [16] [17] [19] [20] [21] In Quebec (Canada), permanent residents who are 65 years and older benefit from a comprehensive governmental drug coverage whereby all subjects can receive statins with no or very low copayments required. Depending on net family income, annual premiums vary from $0 to $660 and monthly co-payment can be nil or up to 34.5% of drug cost to a maximum of $86. 22 Even though the consequences of their non-adherence can be life-threatening, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] it remains unclear whether patients with STEMI who benefit from low/no-cost drug dispensation have optimal long-term adherence to statins. We aimed to evaluate 10-year adherence to statin in STEMI survivors in Quebec, Canada.
MeThodS

Study Cohort
The Acute Myocardial Infarction (AMI)-QUEBEC Study is an observational cohort study of patients with a primary discharge diagnosis of STEMI admitted at 17 participating hospitals in the province of Quebec from January 1 st to December 31 st , 2003 . The details of this study have been previously described. 23 We linked the AMI-QUEBEC data set with the provincial administrative databases. We performed data linkage by matching patients in the provincial administrative databases with patients enrolled in the AMI-QUEBEC study based on initials, birthdates, sex, admitting hospitals and dates of STEMI. The health provincial data sets used were those of the provincial medical insurance board (Régie de l'Assurance Maladie du Québec (RAMQ)), the Quebec Civil Status Registry which records deaths (deaths registered in the Registre de l'État Civil du Québec) and the provincial hospitalization records (MedECHO).
For the purposes of this study, we included only patients who fulfilled all of the following criteria: (1) survived the index STEMI, (2) health information could be retrieved from the provincial administrative data sets between 
Study Variables
All the baseline characteristics were captured at the time of the index STEMI. We evaluated adherence by calculating the proportion of days covered (PDC), which was defined by the total length of statin therapy in days divided by the number of days of follow-up. Optimal adherence was defined as a PDC of ≥ 80%. The validity of PDC and its cut-off of 80% had been validated to evaluate adherence to medications. 13, 14 Patients were considered adherent if their PDC was ≥ 80% during the whole follow-up period (excluding hospitalizations, when they would have received in-hospital statin dispensation). For patients with nonpersistence to statins, we stopped measuring PDC after the last statin dispensation during the 10-year follow-up. Therefore, we measured PDC only while patients were still taking the statins. Follow-up period was defined as the period from the day of discharge after the index STEMI to the occurrence of either death or the end of the study (March 31, 2013), whichever occurred earlier.
High-potency statins were defined as either atorvastatin ≥ 40 mg, rosuvastatin ≥ 20 mg or simvastatin 80 mg. All other types and doses of statin were considered of low/moderate potency. All other non-statin lipid-lowering therapies (LLT) (ezetimibe, fibrates, colestipol) were analyzed together.
We used the Quebec's National Public Health Institute (Institut National Santé Public du Québec (INSPQ)) deprivation index to evaluate material and social deprivation. This index was constructed based on information from the most current Census Canada for the enumeration area of patients' residences. 24 The deprivation index consists of six socio-economic indicators. Material deprivation was based on (1) proportion of people aged 15 years and older with no high school diploma, (2) population/employment ratio of people aged 15 years and older and (3) average income of people aged 15 years and older. Social deprivation was based on (1) proportion of individuals aged 15 years and older living alone, (2) proportion of individuals aged 15 years and older whose marital status is either separated, divorced, or widowed and (3) proportion of single-parent families. Each enumeration area received a score separately for material and social deprivation. The scores were further stratified into quintiles with Quintile 1 (Q1) representing the least deprived, and Quintile 5 (Q5) being the most deprived. For this study, RAMQ provided the material and social deprivation quintiles for all of the patients included in our cohort.
Statistical Analyses
We used Student's t-test for comparison of continuous variables and chi-squared tests for categorical variables between adherent and non-adherent patients. Multivariate logistic regression was used to identify patient characteristics associated with statin adherence. For both models, the variables were selected using a stepwise algorithm with a significance level of 0.30 for entry and a significance level of 0.10 for inclusion. All analyses were done with SAS Enterprise Guide 7.1. there were 858 patients with successfully retrieved long-term health data from the provincial health data sets. We further excluded 311 patients who did not have drug insurance with the RAMQ. Then, we excluded 23 patients who did not receive any statin during the study period. The final study cohort was composed of 524 patients who filled at least 1-month supply of statin following the index STEMI. Of this cohort, 475 (91%) were still alive at 10 years.
ReSulTS
Figure
The mean age of the study cohort was 64 years and 32% were females; 13% of patients had diabetes mellitus and 22% had prior CV events ( Table 1) . Seventy-two percent of patients filled their statin prescription on the day of hospital discharge and 81% of patients filled their prescription within the first month of hospital (Figure 2 ). Ten percent of patients filled their statin prescription more than 5 months after the index STEMI (4% beyond one year). During the first five years, LLT was dispensed in most patients (99%); this proportion declined to 88% during the last 5 years ( Figure 3 ). Statins were the predominant type of LLT (89% and 78% of patients, during the first 5 years and during the last 5 years, respectively) ( Figure 3 ). Nonstatin LLT were used in approximately 10% of patients and mostly in combination with statins. High-potency statins (with/without other types of LLT) were infrequently used with only 8% of patients who received statin at discharge of the index STEMI and 36% of patients who received statin at the last dispensation during the 10-year follow-up ( Figure 4 ). During the first year, 81% of patients were optimally adherent to statins; this percentage increased over the 10-year follow-up and reached 87% during the last year of follow-up ( Figure 5 ). The percentages of patients with low statin adherence (21%-60%) and very low statin adherence (<20%) remained stable at <12% during most of the study period, with the lowest at 8% during the last year. We observed a U-shape relationship between age and PDC with the highest PDC in patients aged between 60 and 80 years old ( Figure 6 ). 
FIG. 6
Relationship between proportion of days covered and age. We showed the independent predictors of optimal adherence in Table 2 . Older age (up to the age of 80), living in areas within the two least socially deprived areas (Q1 and Q2), admission to a PCIhospital and concomitant use of ACEI or ARB at hospital discharge were associated with increases in odds of optimal adherence. Living in the least socially deprived areas Q1 and Q2 were associated with two and three-fold increases in odds of optimal adherence, respectively. Being prescribed ACEI or ARB at hospital discharge and admission to a PCI-hospital were associated with two-fold and 1.8-fold increases in odds of optimal adherence, respectively. 
dISCuSSIoN
Our study provided insights into statin adherence over a long time horizon of 10 years. We showed that despite low or no-cost for drug dispensation, 12% of STEMI survivors remained non-optimally adherent to statin. Although the majority of patients (60%) filled their statin prescription within the first month of discharge, there remained a minority of patients (10%) who were dispensed statins much later (5 months or more). During the last 5 years, 12% of patients did not use any LLT. Older age, living in less socially deprived areas, concomitant use of ACEI/ARB, admission to PCI-hospitals were associated with improved statin adherence.
The stable rate of optimal adherence of our patients which remained at 80% and more during the 10-year follow-up was a definite improvement compared to previously reported adherence rates at 1-year and 5-year of 80% and 50%, respectively. 3, 8, 13 However, we noted three areas of sub-optimal LLT use: (1) lack of any LLT use in 12% of patients during the last 5 years, (2) although there was a temporal increase in use of high-potency statins, these medications remained under-used despite the well demonstrated benefits of high-potency statins 25, 26 and (3) late statin refill (more than 5 months) in 10% of the STEMI survivors. Considering our low or no-cost statin dispensation and the risk of recurrent ischemia, adherence to LLT should be close to 100% in our cohort and patients unable to receive high-potency statins or any statin at all should have received alternate LLT either in single therapy or combined with statins. 27, 28 Furthermore, all patients should have received expedient statin dispensation and use of high-potency statins should have been more emphasized.
Our analysis sheds some valuable insights into the independent determinants of long-term statin adherence within a system of care with low/no-cost statin dispensation. Age had variable influence on adherence within previous similar contexts with free or low-cost statin dispensation. 3, 21, 22, 29, 30 While Tuppin et al. reported worse adherence in the elderly, 29 others observed better adherence with advanced age. 3, 30 Similar to Mann et al., we observed a U-shape relationship with patients aged from 60 to 80 years old having the most optimal adherence. 30 Our results suggest that even with free or low-cost statin dispensation, other factors may confound the impact of age on statin adherence. Patients with concomitant use of ACEI or ARB were more likely to be adherent to statins in our study. Use of ACEI or ARB may simply be a marker of better general adherence to therapies. Alternatively, concomitant use of ACEI or ARB may be a marker of sicker patients with more depressed cardiac function. Another potential hypothesis would be that concomitant use of ACEI or ARB may decrease side-effects to statins, hence improving long-term adherence to statins. Angiotensin II has been shown to increase oxidation of LDL. 31 It is therefore possible that by its anti-inflammatory action, angiotensin-renin blockade may have a direct benefit in decreasing inflammatory myopathy/myalgia in patients prone to statin intolerance. This hypothesis may be worth further exploration in larger studies.
Although PCI during the index STEMI hospitalization was not significantly associated with improved adherence, patients admitted at hospitals with an on-site PCI facility were twice more likely to be adherent compared to patients admitted at hospitals without on-site PCI facility. We are not aware of any evaluation of type of hospital on long-term statin adherence in STEMI survivors. Hospitals with on-site PCI facility are generally teaching hospitals with larger annual volumes of patients with STEMI. The impact of hospital's teaching status was variable in survivors of MI 32, 33 with lower mortality in patients admitted at teaching hospitals 32 and neutral in other study. 33 It was possible, that in addition to the PCI facility, these institutions may offer better services to enhance support of STEMI survivors (such as cardiac rehabilitation or availability of lipidologists). Thereby, statin adherence may be improved in STEMI survivors by these aspects of care.
Little is known on the impact of social deprivation on long-term adherence to statins. Socially deprived areas in our study were areas with the most individuals who were either single, divorced, widowed, living alone or from a single-parent family. Socially deprived patients may not have the social support and encouragement which may improve long-term adherence to statin. Although the impact of social network was not consistently associated with medication adherence, many of these studies were completed in patients with non-CV diseases (mainly immunodeficiency diseases). 34 It is therefore possible that social deprivation has more prominent impact on statin adherence than on adherence to other medications. In contrast to previous authors. 16, 17, 19, 21 we did not observe any effect of material deprivation on adherence to statins. This may be due to our low/no-cost statin dispensation.
lIMITATIoNS
Our study had a few noteworthy limitations. First, we had to exclude 213 patients (19% of our cohort) due to non-availability of their 10-year health data. Compared to patients with available 10-year health data, the excluded patients were older with more high-risk features (Appendix 2). Exclusion of these patients may have over-estimated our measures of adherence. Second, due to the inclusion of only patients with provincial drug coverage, our patients were particularly vulnerable individuals; such as elderly (≥65 years old) and/or individuals with low income. Our findings therefore may not be entirely generalizable to younger patients and those with private drug insurance. Nevertheless, it remains highly likely that some of our observations such as the association of social deprivation with decreased adherence may be able to be replicated in different populations of patients. Third, we did not capture data on side-effects to statins, reasons for statin discontinuation and lipid profiles This information would have been useful for our understanding of obstacles to statin adherence or low use of high-potency statins. Finally, the INSPQ evaluation of social deprivation was based mainly on the residential areas of the patients. Consequently, this assessment was subject to potential ecological bias whereby unknown confounders other than social deprivation may have modified statin adherence.
Compared to most prior studies of adherence, the strength of our analysis is based on complete statin refills information adjusted for hospitalizations stays (when patients would not be able to take prescribed medications). Finally, the length of our follow-up exceeded most prior cohort studies on statin adherence. 2, 3, 8, [16] [17] [18] 21, 22, 29 
CoNCluSIoNS
Despite the low/no-cost medication dispensation, a minority of STEMI survivors were not using any type of LLT including statins during the long-term follow-up. Older age (up to 80 years), living in less socially deprived areas, concomitant use of ACEI or ARB, and admission to PCI-hospitals were associated with improved statin adherence. Future studies are needed to explore the potential factors associated with concomitant use of ACEI/ARB, and admission to PCI-hospitals that may have optimized statin adherence. Finally, socially deprived patients (single, widow, single-parent family member and those who lived alone) may benefit from more support and encouragement to enhance their long-term statin adherence.
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